DK3254675T3 - Orale doseringssammensætninger med forsinket frigivelse, der indeholder amorf cddo-me - Google Patents

Orale doseringssammensætninger med forsinket frigivelse, der indeholder amorf cddo-me Download PDF

Info

Publication number: DK3254675T3
Authority: DK; Denmark
Prior art keywords: amorf; cddo; oral dosage; delayed delivery; delivery containing
Prior art date: 2009-02-13

Application number

DK17181174.8T

Other languages

English (en)

Inventor

Jiang Zhang

Colin J Meyer

Original Assignee

Reata Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-02-13

Filing date

2010-02-12

Publication date

2019-06-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42335073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3254675(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-02-12 Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc

2019-06-24 Application granted granted Critical

2019-06-24 Publication of DK3254675T3 publication Critical patent/DK3254675T3/da

Links

206010012186 Delayed delivery Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DK17181174.8T 2009-02-13 2010-02-12 Orale doseringssammensætninger med forsinket frigivelse, der indeholder amorf cddo-me DK3254675T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15260809P	2009-02-13	2009-02-13
EP10704298.8A EP2395979B1 (en)	2009-02-13	2010-02-12	Delayed release, oral dosage compositions that contain amorphous cddo-me

Publications (1)

Publication Number	Publication Date
DK3254675T3 true DK3254675T3 (da)	2019-06-24

Family

ID=42335073

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK17181174.8T DK3254675T3 (da)	2009-02-13	2010-02-12	Orale doseringssammensætninger med forsinket frigivelse, der indeholder amorf cddo-me
DK10704298.8T DK2395979T3 (da)	2009-02-13	2010-02-12	Orale doseringssammensætninger med forsinket frigivelse, der indeholder amorft ccdo-me

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK10704298.8T DK2395979T3 (da)	2009-02-13	2010-02-12	Orale doseringssammensætninger med forsinket frigivelse, der indeholder amorft ccdo-me

Country Status (30)

Country	Link
US (2)	US8747901B2 (da)
EP (2)	EP2395979B1 (da)
JP (1)	JP5775464B2 (da)
KR (2)	KR20140016441A (da)
CN (2)	CN102387789A (da)
AU (1)	AU2010213594B2 (da)
BR (1)	BRPI1008023B8 (da)
CA (1)	CA2752048C (da)
CO (1)	CO6361904A2 (da)
CY (2)	CY1119595T1 (da)
DK (2)	DK3254675T3 (da)
EA (1)	EA023652B1 (da)
ES (2)	ES2646816T3 (da)
HK (1)	HK1220130A1 (da)
HR (2)	HRP20171639T1 (da)
HU (2)	HUE044005T2 (da)
IL (1)	IL214258A (da)
LT (2)	LT3254675T (da)
MX (1)	MX2011008344A (da)
MY (1)	MY173715A (da)
NO (1)	NO2395979T3 (da)
NZ (1)	NZ594488A (da)
PL (2)	PL3254675T3 (da)
PT (2)	PT2395979T (da)
SG (1)	SG173601A1 (da)
SI (2)	SI3254675T1 (da)
SM (2)	SMT201900432T1 (da)
TR (1)	TR201909743T4 (da)
WO (1)	WO2010093944A2 (da)
ZA (1)	ZA201105630B (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6326507B1 (en)	1998-06-19	2001-12-04	Trustees Of Dartmouth College	Therapeutic compounds and methods of use
HUE043175T2 (hu)	2008-01-11	2019-08-28	Reata Pharmaceuticals Inc	Szintetikus triterpenoidok és alkalmazásuk betegség kezelésében
MX339476B (es)	2008-04-18	2016-05-27	Reata Pharmaceuticals Inc	Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
CN104250280A (zh)	2008-04-18	2014-12-31	里亚塔医药公司	抗氧化剂炎症调节剂:c-17同系化齐墩果酸衍生物
ES2703274T3 (es)	2008-04-18	2019-03-07	Reata Pharmaceuticals Inc	Moduladores de la inflamación antioxidantes: derivados del ácido oleanólico con modificaciones amino y otras en C-17
KR101713140B1 (ko)	2008-04-18	2017-03-08	리타 파마슈티컬스 잉크.	Ｃ-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체
EP2309860B1 (en)	2008-07-22	2014-01-08	Trustees of Dartmouth College	Monocyclic cyanoenones and methods of use thereof
PL3254675T3 (pl)	2009-02-13	2019-09-30	Reata Pharmaceuticals, Inc.	Kompozycje doustne o opóźnionym uwalnianiu, zawierające amorficzny cddo-me
SMT202000086T1 (it)	2010-04-12	2020-03-13	Reata Pharmaceuticals Inc	Bardoxolone metile per il trattamento dell'obesità
HRP20171859T1 (hr)	2010-12-17	2018-01-26	Reata Pharmaceuticals, Inc.	Pirazolil i pirimidinil triciklički enoni kao antioksidacijski modulatori upale
CA2829618C (en)	2011-03-11	2019-07-09	Reata Pharmaceuticals, Inc.	C4-monomethyl triterpenoid derivatives and methods of use thereof
CN103156861B (zh) *	2011-12-08	2015-11-25	陈丽梅	齐敦果酸衍生物及其可药用盐在治疗糖尿病眼病中的应用
US20130158077A1 (en)	2011-12-19	2013-06-20	Ares Trading S.A.	Pharmaceutical compositions
US9504679B2 (en)	2011-12-19	2016-11-29	Bjoern Colin Kahrs	Pharmaceutical compositions comprising glitazones and Nrf2 activators
DK3444261T3 (da)	2012-04-27	2021-03-08	Reata Pharmaceuticals Inc	2,2-difluorpropionamidderivat af bardoxolonmethyl, farmaceutiske sammensætninger og polymorfer deraf til anvendelse ved behandling af visse lidelser
US8981144B2 (en)	2012-05-08	2015-03-17	Trustees Of Dartmouth College	Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof
US8921419B2 (en)	2012-05-08	2014-12-30	Trustees Of Dartmouth College	Triterpenoids and compositions containing the same
US9556222B2 (en)	2012-06-15	2017-01-31	Reata Pharmaceuticals, Inc.	A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9512094B2 (en)	2012-09-10	2016-12-06	Reata Pharmaceuticals, Inc.	C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
US9278912B2 (en)	2012-09-10	2016-03-08	Reata Pharmaceuticals, Inc.	C13-hydroxy derivatives of oleanolic acid and methods of use thereof
PL2892912T3 (pl)	2012-09-10	2019-10-31	Reata Pharmaceuticals Inc	C17-alkanodiylowe i alkenodiylowe pochodne kwasu oleanolowego i sposoby ich zastosowania
TWI649330B (zh)	2013-04-24	2019-02-01	艾伯維有限公司	甲基巴多索龍之２，２－二氟丙醯胺衍生物、其多晶形及其使用方法
NZ774222A (en)	2013-08-23	2023-01-27	Reata Pharmaceuticals Holdings Llc	Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
WO2016070063A1 (en)	2014-10-31	2016-05-06	The Regents Of The University Of California	Compositions and methods for treating hiv-associated cognitive dysfunction
US11059792B2 (en)	2015-02-12	2021-07-13	Reata Pharmaceuticals, Inc.	Imidazolyl tricyclic enones as antioxidant inflammation modulators
EA201890767A1 (ru)	2015-09-23	2019-09-30	Рита Фармасьютикалз, Инк.	C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
AU2017356955B2 (en)	2016-11-08	2023-11-09	Reata Pharmaceuticals Holdings, LLC	Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof
TWI831738B (zh)	2016-12-16	2024-02-11	美商瑞塔醫藥有限責任公司	用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
WO2019014412A1 (en)	2017-07-13	2019-01-17	Pliva Hrvatska D.O.O.	NOVEL CRYSTALLINE POLYMORPHIC FORMS OF METHYL BARDOXOLONE
JP7244536B2 (ja)	2018-04-06	2023-03-22	キャプシュゲル・ベルジウム・エヌ・ヴィ	メタクリル酸メチル－メタクリル酸コポリマーからなる低アスペクト比の粒子のための噴霧乾燥方法
CN112654610B (zh)	2018-06-15	2024-12-24	里亚塔医药公司	用于抑制IL-17和RORγ的吡唑和咪唑化合物
EP3810141A1 (en)	2018-06-20	2021-04-28	Reata Pharmaceuticals, Inc.	Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
WO2020111089A1 (ja)	2018-11-27	2020-06-04	協和キリン株式会社	医薬組成物
CN114126408A (zh) *	2019-05-31	2022-03-01	戴纳立制药公司	嘧啶基氨基-吡唑化合物的改良释放配制品和治疗方法
KR102891865B1 (ko)	2019-07-19	2025-11-26	리아타 파마슈티컬즈, 아이엔씨.	C17 극성-치환된 헤테로방향족 합성 트리터페노이드 및 그의 사용 방법
IL298008A (en)	2020-05-09	2023-01-01	Reata Pharmaceuticals Holdings Llc	Methods for treating covid-19 with the help of bardoxolone methyl or its analogs
EP4259155A1 (en)	2020-12-11	2023-10-18	Reata Pharmaceuticals Holdings, LLC	Synthetic triterpenoids for use in therapy
CN114558019A (zh) *	2022-03-26	2022-05-31	中国科学院昆明动物研究所	一种Rab13基因抑制剂及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6326507B1 (en)	1998-06-19	2001-12-04	Trustees Of Dartmouth College	Therapeutic compounds and methods of use
US7435755B2 (en) *	2000-11-28	2008-10-14	The Trustees Of Dartmouth College	CDDO-compounds and combination therapies thereof
JP2008110962A (ja) *	2006-08-02	2008-05-15	Santen Pharmaceut Co Ltd	Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤
JP4315182B2 (ja) *	2006-10-30	2009-08-19	ミツミ電機株式会社	カメラモジュール
WO2008111497A1 (ja) *	2007-03-08	2008-09-18	Santen Pharmaceutical Co., Ltd.	トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
US8088824B2 (en) *	2007-08-15	2012-01-03	Reata Pharmaceuticals Inc.	Forms of CDDO methyl ester
HUE043175T2 (hu)	2008-01-11	2019-08-28	Reata Pharmaceuticals Inc	Szintetikus triterpenoidok és alkalmazásuk betegség kezelésében
PL3254675T3 (pl)	2009-02-13	2019-09-30	Reata Pharmaceuticals, Inc.	Kompozycje doustne o opóźnionym uwalnianiu, zawierające amorficzny cddo-me

2010
- 2010-02-12 PL PL17181174T patent/PL3254675T3/pl unknown
- 2010-02-12 BR BRPI1008023A patent/BRPI1008023B8/pt active IP Right Grant
- 2010-02-12 SI SI201031906T patent/SI3254675T1/sl unknown
- 2010-02-12 PT PT107042988T patent/PT2395979T/pt unknown
- 2010-02-12 LT LTEP17181174.8T patent/LT3254675T/lt unknown
- 2010-02-12 WO PCT/US2010/024127 patent/WO2010093944A2/en not_active Ceased
- 2010-02-12 KR KR1020147001850A patent/KR20140016441A/ko not_active Withdrawn
- 2010-02-12 PT PT17181174T patent/PT3254675T/pt unknown
- 2010-02-12 HR HRP20171639TT patent/HRP20171639T1/hr unknown
- 2010-02-12 EP EP10704298.8A patent/EP2395979B1/en active Active
- 2010-02-12 HU HUE17181174A patent/HUE044005T2/hu unknown
- 2010-02-12 KR KR1020117021250A patent/KR101483203B1/ko active Active
- 2010-02-12 HU HUE10704298A patent/HUE035013T2/en unknown
- 2010-02-12 SI SI201031570T patent/SI2395979T1/sl unknown
- 2010-02-12 AU AU2010213594A patent/AU2010213594B2/en active Active
- 2010-02-12 CN CN201080007105XA patent/CN102387789A/zh active Pending
- 2010-02-12 DK DK17181174.8T patent/DK3254675T3/da active
- 2010-02-12 EP EP17181174.8A patent/EP3254675B1/en active Active
- 2010-02-12 NZ NZ594488A patent/NZ594488A/xx unknown
- 2010-02-12 NO NO10704298A patent/NO2395979T3/no unknown
- 2010-02-12 US US13/201,398 patent/US8747901B2/en active Active
- 2010-02-12 JP JP2011550279A patent/JP5775464B2/ja active Active
- 2010-02-12 SM SM20190432T patent/SMT201900432T1/it unknown
- 2010-02-12 CA CA2752048A patent/CA2752048C/en active Active
- 2010-02-12 TR TR2019/09743T patent/TR201909743T4/tr unknown
- 2010-02-12 ES ES10704298.8T patent/ES2646816T3/es active Active
- 2010-02-12 MX MX2011008344A patent/MX2011008344A/es active IP Right Grant
- 2010-02-12 DK DK10704298.8T patent/DK2395979T3/da active
- 2010-02-12 EA EA201190092A patent/EA023652B1/ru not_active IP Right Cessation
- 2010-02-12 ES ES17181174T patent/ES2731601T3/es active Active
- 2010-02-12 MY MYPI2011003694A patent/MY173715A/en unknown
- 2010-02-12 LT LTEP10704298.8T patent/LT2395979T/lt unknown
- 2010-02-12 PL PL10704298T patent/PL2395979T3/pl unknown
- 2010-02-12 SG SG2011057122A patent/SG173601A1/en unknown
- 2010-02-12 CN CN201510540397.8A patent/CN105232471A/zh active Pending
- 2010-02-12 SM SM20170527T patent/SMT201700527T1/it unknown
2011
- 2011-07-24 IL IL214258A patent/IL214258A/en active IP Right Grant
- 2011-07-29 ZA ZA2011/05630A patent/ZA201105630B/en unknown
- 2011-08-09 CO CO11100847A patent/CO6361904A2/es not_active Application Discontinuation
2014
- 2014-04-30 US US14/266,031 patent/US9155721B2/en active Active
2016
- 2016-07-13 HK HK16108241.2A patent/HK1220130A1/zh unknown
2017
- 2017-11-13 CY CY20171101183T patent/CY1119595T1/el unknown
2019
- 2019-06-17 HR HRP20191092 patent/HRP20191092T1/hr unknown
- 2019-07-17 CY CY20191100761T patent/CY1122066T1/el unknown

Also Published As

Publication number	Publication date
LT3254675T (lt)	2019-06-25
ES2646816T3 (es)	2017-12-18
SI3254675T1 (sl)	2019-08-30
HK1220130A1 (zh)	2017-04-28
EP2395979B1 (en)	2017-08-23
US20140235711A1 (en)	2014-08-21
DK2395979T3 (da)	2017-11-27
AU2010213594A1 (en)	2011-08-18
SMT201700527T1 (it)	2018-01-11
HRP20191092T1 (hr)	2019-11-29
PT2395979T (pt)	2017-11-16
BRPI1008023A2 (pt)	2016-03-15
PL2395979T3 (pl)	2018-02-28
HUE044005T2 (hu)	2019-09-30
CA2752048A1 (en)	2010-08-19
AU2010213594B2 (en)	2013-11-14
ES2731601T3 (es)	2019-11-18
CN102387789A (zh)	2012-03-21
IL214258A0 (en)	2011-09-27
US8747901B2 (en)	2014-06-10
MY173715A (en)	2020-02-18
US9155721B2 (en)	2015-10-13
SI2395979T1 (sl)	2017-12-29
CO6361904A2 (es)	2012-01-20
CN105232471A (zh)	2016-01-13
PL3254675T3 (pl)	2019-09-30
KR20140016441A (ko)	2014-02-07
LT2395979T (lt)	2017-12-11
KR20110118721A (ko)	2011-10-31
MX2011008344A (es)	2011-09-29
IL214258A (en)	2017-06-29
WO2010093944A3 (en)	2011-08-11
HRP20171639T1 (hr)	2017-12-15
BRPI1008023B1 (pt)	2019-12-31
CA2752048C (en)	2014-11-25
US20120022156A1 (en)	2012-01-26
CY1122066T1 (el)	2020-11-25
EP3254675B1 (en)	2019-05-15
EP3254675A1 (en)	2017-12-13
ZA201105630B (en)	2012-04-25
EA201190092A1 (ru)	2012-02-28
NO2395979T3 (da)	2018-01-20
HUE035013T2 (en)	2018-05-02
PT3254675T (pt)	2019-06-14
EA023652B1 (ru)	2016-06-30
NZ594488A (en)	2013-10-25
TR201909743T4 (tr)	2019-07-22
BRPI1008023B8 (pt)	2023-04-11
JP2012518008A (ja)	2012-08-09
SG173601A1 (en)	2011-09-29
WO2010093944A2 (en)	2010-08-19
EP2395979A2 (en)	2011-12-21
SMT201900432T1 (it)	2019-09-09
KR101483203B1 (ko)	2015-01-15
CY1119595T1 (el)	2018-03-07
JP5775464B2 (ja)	2015-09-09

Publication	Publication Date	Title
DK2395979T3 (da)	2017-11-27	Orale doseringssammensætninger med forsinket frigivelse, der indeholder amorft ccdo-me
IL227113B (en)	2018-04-30	Tamper resistant solid oral dosage forms
GB2491327B (en)	2017-05-10	Delayed prolonged drug delivery
GB0909680D0 (en)	2009-07-22	Dosage form
PL2493457T3 (pl)	2018-01-31	Szybko rozpuszczalna stała postać dawkowana
BRPI1010772A2 (pt)	2016-11-01	composto,e, composição farmacêutica.
ZA201304158B (en)	2014-12-23	Dosage form
IL222353A0 (en)	2012-12-31	Very low-dosed solid oral dosage forms for hrt
SMT201700095B (is)	2017-03-08	Composizioni farmaceutiche per inalazione
SI2645992T1 (sl)	2020-02-28	Trdna oralna dozirna oblika z asimetrično obliko
SMT201600341B (it)	2016-11-10	Soluzione per somministrazione orale
BRPI1015365A2 (pt)	2016-04-19	colher dosadora com grampo.
EP2460415A4 (en)	2014-02-19	COATED PREPARATION
DK2437736T3 (da)	2017-11-13	Lægemiddelindgivelsessystemer
ZA201204429B (en)	2013-02-27	Ethynyl derivatives
BR112012031102A2 (pt)	2015-09-22	forma de dosagem oral sólida
EP2732809A4 (en)	2014-08-27	ORAL COMPOSITION
ZA201302112B (en)	2013-12-23	1,4-oxazepane derivatives
GB0822124D0 (en)	2009-01-07	Oral dosage form
BR112014016122A2 (pt)	2017-06-13	composto, e, composição farmacêutica
BR112012002293A2 (pt)	2016-06-14	composto, composição farmacêutica, e, uso do composto
GB0802576D0 (en)	2008-03-19	Dosage form
GB201018760D0 (en)	2010-12-22	An oral dosage form
FIU20090464U0 (fi)	2009-12-21	Yhden pyöräytyksen annostelija
GB201011271D0 (en)	2010-08-18	Dosage Form